Terms: = Sarcomas AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Prognosis
15 results:
1. Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm fgfr4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Timpanaro A; Piccand C; Uldry AC; Bode PK; Dzhumashev D; Sala R; Heller M; Rössler J; Bernasconi M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768928
[TBL] [Abstract] [Full Text] [Related]
2. Mutational landscape of primary breast angiosarcoma with repeated resection and recurrence over a 15-year period: A case report.
Teruyama F; Kuno A; Murata Y; Nakagawa T; Shiba-Ishii A; Yuguchi S; Noguchi M
Pathol Int; 2022 Sep; 72(9):457-463. PubMed ID: 35801418
[TBL] [Abstract] [Full Text] [Related]
3. Deciphering the Genomic Landscape and Pharmacological Profile of Uncommon Entities of Adult Rhabdomyosarcomas.
De Vita A; Vanni S; Fausti V; Cocchi C; Recine F; Miserocchi G; Liverani C; Spadazzi C; Bassi M; Gessaroli M; Campobassi A; De Luca G; Pieri F; Farnedi A; Franchini E; Ferrari A; Domizio C; Cavagna E; Gurrieri L; Bongiovanni A; Riva N; Calpona S; Di Menna G; Debonis SA; Ibrahim T; Mercatali L
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768995
[TBL] [Abstract] [Full Text] [Related]
4. fgfr4 promotes nuclear localization of GABP to inhibit cell apoptosis in uterine leiomyosarcoma.
Zhang P; Zhang H; Wang Y
Cell Tissue Res; 2021 Feb; 383(2):865-879. PubMed ID: 33151453
[TBL] [Abstract] [Full Text] [Related]
5. Update on molecular findings in rhabdomyosarcoma.
El Demellawy D; McGowan-Jordan J; de Nanassy J; Chernetsova E; Nasr A
Pathology; 2017 Apr; 49(3):238-246. PubMed ID: 28256213
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor.
Zhou W; Du X; Song F; Zheng H; Chen K; Zhang W; Yang J
Oncotarget; 2016 Apr; 7(16):22234-44. PubMed ID: 26993773
[TBL] [Abstract] [Full Text] [Related]
7. Germline variant fgfr4 p.G388R exposes a membrane-proximal STAT3 binding site.
Ulaganathan VK; Sperl B; Rapp UR; Ullrich A
Nature; 2015 Dec; 528(7583):570-4. PubMed ID: 26675719
[TBL] [Abstract] [Full Text] [Related]
8. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.
Seki M; Nishimura R; Yoshida K; Shimamura T; Shiraishi Y; Sato Y; Kato M; Chiba K; Tanaka H; Hoshino N; Nagae G; Shiozawa Y; Okuno Y; Hosoi H; Tanaka Y; Okita H; Miyachi M; Souzaki R; Taguchi T; Koh K; Hanada R; Kato K; Nomura Y; Akiyama M; Oka A; Igarashi T; Miyano S; Aburatani H; Hayashi Y; Ogawa S; Takita J
Nat Commun; 2015 Jul; 6():7557. PubMed ID: 26138366
[TBL] [Abstract] [Full Text] [Related]
9. Targeting wild-type and mutationally activated fgfr4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
[TBL] [Abstract] [Full Text] [Related]
10. Expression of FGFR3 and fgfr4 and clinical risk factors associated with progression-free survival in synovial sarcoma.
Charbonneau B; Vogel RI; Manivel JC; Rizzardi A; Schmechel SC; Ognjanovic S; Subramanian S; Largaespada D; Weigel B
Hum Pathol; 2013 Sep; 44(9):1918-26. PubMed ID: 23664540
[TBL] [Abstract] [Full Text] [Related]
11. fgfr4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.
Dutra RL; de Carvalho MB; Dos Santos M; Mercante AM; Gazito D; de Cicco R; Group G; Tajara EH; Louro ID; da Silva AM
PLoS One; 2012; 7(11):e50747. PubMed ID: 23226373
[TBL] [Abstract] [Full Text] [Related]
12. Meta and pooled analyses of fgfr4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract] [Full Text] [Related]
13. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Cao L; Yu Y; Bilke S; Walker RL; Mayeenuddin LH; Azorsa DO; Yang F; Pineda M; Helman LJ; Meltzer PS
Cancer Res; 2010 Aug; 70(16):6497-508. PubMed ID: 20663909
[TBL] [Abstract] [Full Text] [Related]
14. The fibroblast growth factor receptor 4 (fgfr4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract] [Full Text] [Related]
15. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
[TBL] [Abstract] [Full Text] [Related]
